These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37526843)

  • 1. United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies.
    Sanduja S; Lessey-Morillon L; Allen R; Wang X; Imperato G; Arcidiacono J
    Adv Exp Med Biol; 2023; 1430():71-89. PubMed ID: 37526843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications.
    Lin X; Lee S; Scott J; Lin M
    Ther Innov Regul Sci; 2021 Mar; 55(2):346-359. PubMed ID: 32955712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory issues in clinical applications of cytokines and growth factors.
    Weiss KD; Siegel JP; Gerrard TL
    Prog Growth Factor Res; 1994; 5(2):213-22. PubMed ID: 7919225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Regulatory Pathways Used to Develop, Evaluate, Authorize, and Approve New Drugs and Vaccines in the United States.
    Domachowske JB
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S93-S102. PubMed ID: 38995086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tutorial on How the US Food and Drug Administration Regulates Parenteral Nutrition Products.
    Tabor E
    JPEN J Parenter Enteral Nutr; 2020 Feb; 44(2):174-181. PubMed ID: 31971272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval.
    Hirani K; Bansinath M; Mittal R; Lemos JRN; Adis E; Poojari P; Igoe JM; Soares MR; Bhattacharya S; Weiss RE
    J Ocul Pharmacol Ther; 2023 Oct; 39(8):572-582. PubMed ID: 37797226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory concerns in human gene therapy.
    Epstein SL
    Hum Gene Ther; 1991; 2(3):243-9. PubMed ID: 1751592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.